rhFGF-2联合DBBM与单用rhFGF-2治疗牙周骨内缺损的6个月随机对照试验
两组临床附着获得无显著差异,但联合组影像学骨充填显著更优(47.2%对29.3%),患者报告结局无组间差异。
要点
- 联合DBBM未在6个月时显著改善临床附着获得或患者报告结局。
- 联合DBBM组的影像学骨充填显著优于单用rhFGF-2组。
- 两组从基线到术后6个月的临床附着水平均有显著改善。
核心结论
- 术后6个月,联合治疗与单用rhFGF-2在临床附着获得和患者报告结局上无显著差异,但联合治疗获得更优的影像学结果。
研究设计与样本
- 随机对照试验,纳入接受初始牙周治疗且骨内缺损深度≥3 mm的牙周炎患者,每位点随机分配至0.3% rhFGF-2+DBBM组(试验组)或单用rhFGF-2组(对照组)。
主要发现
- 术后6个月两组临床附着水平(CAL)较基线均显著改善。
- CAL获得试验组为3.16 ± 1.45 mm,对照组为2.77 ± 1.15 mm,组间无显著差异。
- 影像学骨充填试验组为47.2%,显著大于对照组的29.3%。
- PROM两组间无显著差异。
关键数值与推荐
- 骨内缺损入选标准为深度≥3 mm。
- 试验组使用0.3% rhFGF-2联合DBBM,对照组单用rhFGF-2。
- 6个月CAL获得:试验组3.16 ± 1.45 mm,对照组2.77 ± 1.15 mm,组间无显著差异。
- 影像学骨充填:试验组47.2%,对照组29.3%,试验组显著更大。
临床怎么用
- 对骨内牙周缺损,rhFGF-2单用或联合DBBM均可改善6个月临床附着。
- 若更关注影像学骨充填,可考虑rhFGF-2联合DBBM,但需权衡临床附着与PROM无额外获益。
局限性
- 随访仅至术后6个月,缺乏长期疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate the use of recombinant human fibroblast growth factor (rhFGF)-2 in combination with deproteinized bovine bone mineral (DBBM) compared with rhFGF-2 alone, in the treatment of intrabony periodontal defects. MATERIALS AND METHODS: Patients with periodontitis who had received initial periodontal therapy and had intrabony defects of ≥ 3 mm in depth were enrolled. Sites were randomly assigned to receive a commercial formulation of 0.3% rhFGF-2 + DBBM (test) or rhFGF-2 alone (control). Clinical parameters and a patient-reported outcome measure (PROM) were evaluated at baseline and at 3 and 6 months postoperatively. RESULTS: Twenty-two sites in each group were evaluated. A significant improvement in clinical attachment level (CAL) from baseline was observed in both groups at 6 months postoperatively. CAL gain was 3.16 ± 1.45 mm in the test group and 2.77 ± 1.15 mm in the control group, showing no significant difference between groups. Radiographic bone fill was significantly greater in the test group (47.2%) than in the control group (29.3%). No significant difference in PROM between groups was observed. CONCLUSIONS: At 6 months, no significant difference in CAL gain or PROM between the two treatments was observed, although combination therapy yielded an enhanced radiographic outcome.
引用
- Saito A, Bizenjima T, Takeuchi T, et al. Treatment of intrabony periodontal defects using rhFGF-2 in combination with deproteinized bovine bone mineral or rhFGF-2 alone: A 6-month randomized controlled trial. J Clin Periodontol. 2019. PMID: 30758076. doi:10.1111/jcpe.13086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。